Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort

被引：19

作者：

Arora, Mukta ^{[1
]}

Hemmer, Michael T. ^{[2
]}

Ahn, Kwang Woo ^{[2
,3
]}

Klein, John P. ^{[2
,3
]}

Cutler, Corey S. ^{[4
]}

Urbano-Ispizua, Alvaro ^{[5
,6
]}

Courie, Daniel R. ^{[7
]}

Alousi, Amin M. ^{[8
]}

Gale, Robert Peter ^{[9
]}

Inamoto, Yoshihiro ^{[10
]}

Weisdorf, Daniel J. ^{[1
]}

Li, Peigang

Antin, Joseph H. ^{[4
]}

Bolwell, Brian J. ^{[11
]}

Boyiadzis, Michael ^{[12
]}

Cahn, Jean-Yves ^{[13
]}

Cairo, Mitchell S. ^{[14
]}

Isola, Luis M. ^{[15
]}

Jacobsohn, David A. ^{[16
]}

Jagasia, Madan ^{[17
]}

Klumpp, Thomas R. ^{[18
]}

Petersdorf, Effie W. ^{[19
]}

Santarone, Stella ^{[20
]}

Schouten, Harry C. ^{[21
]}

Wingard, John R. ^{[22
,23
]}

Spellman, Stephen R. ^{[24
]}

Pavletic, Steven Z. ^{[25
]}

Lee, Stephanie J. ^{[19
]}

Horowitz, Mary M. ^{[2
]}

Flowers, Mary E. D. ^{[19
]}

机构：

[1] Univ Minnesota, Med Ctr, Div Hematol Oncol & Transplantat, Dept Med, Minneapolis, MN 55455 USA

[2] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplantat Res, Dept Med, Milwaukee, WI 53226 USA

[3] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA

[4] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA

[5] Univ Barcelona, Dept Hematol, Hosp Clin, IDIBAPS, Barcelona, Spain

[6] Inst Res Josep Carreras, Barcelona, Spain

[7] Univ Michigan, Dept Internal Med, Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplant & Cellular Therapy, Houston, TX 77030 USA

[9] Univ London Imperial Coll Sci Technol & Med, Hematol Res Ctr, Div Expt Med, Dept Med, London, England

[10] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan

[11] Cleveland Clin, Leukemia Program, Hematol Oncol & Blood Disorders, Taussig Canc Inst, Cleveland, OH 44106 USA

[12] Univ Pittsburgh, Dept Med, Ctr Canc, Med Ctr, Pittsburgh, PA USA

[13] Univ Hosp, Dept Hematol, Grenoble, France

[14] New York Med Coll, Dept Pediat Hematol Oncol, Valhalla, NY 10595 USA

[15] Mt Sinai Med Ctr, Div Blood & Marrow Transplantat, New York, NY 10029 USA

[16] Childrens Natl Med Ctr, Div Blood & Marrow Transplantat, Ctr Canc & Blood Disorders, Washington, DC 20010 USA

[17] Vanderbilt Univ, Div Hematol Oncol, Med Ctr, Nashville, TN 37235 USA

[18] Temple Univ, Sch Med, Dept Med, Bone Marrow Transplant Program, Philadelphia, PA 19122 USA

[19] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[20] Osped Civile, Dept Hematol, BMT Ctr, Pescara, Italy

[21] Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands

[22] Shands Canc Ctr, Div Hematol & Oncol, Dept Med, Gainesville, FL USA

[23] Univ Florida, Gainesville, FL USA

[24] Ctr Int Blood & Marrow Transplantat Res, Natl Marrow Donor Program, Minneapolis, MN USA

[25] NCI, NIH, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 04期

关键词：

Chronic graft-versus-host disease (CGVHD); Risk score; Nonrelapse mortality; CHRONIC GVHD; IMMUNOSUPPRESSIVE TREATMENT; CELL TRANSPLANTATION; CONSENSUS CRITERIA; SURVIVAL; OUTCOMES; CLASSIFICATION; PREDNISONE; CONSORTIUM; DURATION;

D O I：

10.1016/j.bbmt.2014.10.022

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all P < .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials. (C) 2015 American Society for Blood and Marrow Transplantation.

引用

页码：640 / 645

页数：6

共 31 条

[21] Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease [J].

Martin, Paul J. ;

Storer, Barry E. ;

Carpenter, Paul A. ;

Couriel, Daniel R. ;

Flowers, Mary E. D. ;

Gupta, Vikas ;

Hsu, Jack W. ;

Jagasia, Madan ;

Kitko, Carrie L. ;

Maziarz, Richard T. ;

Rowley, Scott D. ;

Shaughnessy, Paul J. ;

van Besien, Koen ;

Weisdorf, Daniel ;

Lee, Stephanie J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (01) :124-132

[22]

OCHS LA, 1994, BONE MARROW TRANSPL, V13, P455

[23] Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study [J].

Pidala, Joseph ;

Vogelsang, Georgia ;

Martin, Paul ;

Chai, Xiaoyu ;

Storer, Barry ;

Pavletic, Steven ;

Weisdorf, Daniel J. ;

Jagasia, Madan ;

Cutler, Corey ;

Palmer, Jeanne ;

Jacobsohn, David ;

Arai, Sally ;

Lee, Stephanie J. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03) :451-458

[24] CHRONIC GRAFT VERSUS HOST SYNDROME IN MAN - A LONG-TERM CLINICOPATHOLOGIC STUDY OF 20 SEATTLE PATIENTS [J].

SHULMAN, HM ;

SULLIVAN, KM ;

WEIDEN, PL ;

MCDONALD, GB ;

STRIKER, GE ;

SALE, GE ;

HACKMAN, R ;

TSOI, M ;

STORB, R ;

THOMAS, ED .

AMERICAN JOURNAL OF MEDICINE, 1980, 69 (02) :204-217

[25] Long-term survival and late deaths after allogeneic bone marrow transplantation [J].

Socié, G ;

Stone, JV ;

Wingard, JR ;

Weisdorf, D ;

Henslee-Downey, PJ ;

Bredeson, C ;

Cahn, JY ;

Passweg, JR ;

Rowlings, PA ;

Schouten, HC ;

Kolb, HJ ;

Klein, JP .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (01) :14-21

[26] Duration of immunosuppressive treatment for chronic graft-versus-host disease [J].

Stewart, BL ;

Storer, B ;

Storek, J ;

Deeg, HJ ;

Storb, R ;

Hansen, JA ;

Appelbaum, FR ;

Carpenter, PA ;

Sanders, JE ;

Kiem, HP ;

Nash, RA ;

Petersdorf, EW ;

Moravec, C ;

Morton, AJ ;

Anasetti, C ;

Flowers, MED ;

Martin, PJ .

BLOOD, 2004, 104 (12) :3501-3506

[27] PREDICTIVE FACTORS IN CHRONIC GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH APLASTIC-ANEMIA TREATED BY MARROW TRANSPLANTATION FROM HLA-IDENTICAL SIBLINGS [J].

STORB, R ;

PRENTICE, RL ;

SULLIVAN, KM ;

SHULMAN, HM ;

DEEG, HJ ;

DONEY, KC ;

BUCKNER, CD ;

CLIFT, RA ;

WITHERSPOON, RP ;

APPELBAUM, FA ;

SANDERS, JE ;

STEWART, PS ;

THOMAS, ED .

ANNALS OF INTERNAL MEDICINE, 1983, 98 (04) :461-466

[28]

SULLIVAN KM, 1988, BLOOD, V72, P546

[29] Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD [J].

Vigorito, Afonso C. ;

Campregher, Paulo V. ;

Storer, Barry E. ;

Carpenter, Paul A. ;

Moravec, Carina K. ;

Kiem, Hans-Peter ;

Fero, Matthew L. ;

Warren, Edus H. ;

Lee, Stephanie J. ;

Appelbaum, Frederick R. ;

Martin, Paul J. ;

Flowers, Mary E. D. .

BLOOD, 2009, 114 (03) :702-708

[30] Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival [J].

Weisdorf, Daniel ;

Spellman, Stephen ;

Haagenson, Michael ;

Horowitz, Mary ;

Lee, Stephanie ;

Anasetti, Claudio ;

Setterholm, Michelle ;

Drexler, Rebecca ;

Maiers, Martin ;

King, Roberta ;

Confer, Dennis ;

Klein, John .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (07) :748-758

← 1 2 3 4 →